KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Fei Ma, Min Yan, Wei Li, Quchang Ouyang, Zhongsheng Tong, Yuee Teng, Yongsheng Wang, Shusen Wang, Cuizhi Geng, Ting Luo, Jincai Zhong, Qingyuan Zhang, Qiang Liu, Xiaohua Zeng, Tao Sun, Qinguo Mo, Shoubing Zhou, Peidong Li, Jing Cheng, Xiaojia Wang, Jianyun Nie, Jin Yang, Xinhong Wu, Xinshuai Wang, Huiping Li, Guangyu Yao, Yang Fan, Jiaman Lin, Xiaoyu Zhu, Binghe Xu

BMJ 392 e087259

PMID41839514
PMCIDPMC12990035
DOI10.1136/bmj-2025-087259
发表日期2026-03-16
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

OBJECTIVE: To report updated results of the phase 3 PHILA trial, which evaluated the efficacy and safety of pyrotinib or placebo in combination with trastuzumab and docetaxel in patients with untreated human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer. DESIGN: Multicentre, double blind, randomised, placebo controlled phase 3 trial. SETTING: 40 centres in China, 6 May 2019 to 17 January 2022. PARTICIPANTS: 590 female patients with untreated HER2 positive metastatic breast cancer. INTERVENTIONS: Eligible patients were randomly assigned in a 1:1 ratio to receive either the irreversible pan-HER inhibitor pyrotinib (400 mg orally once daily) or placebo, both in combination with intravenous trastuzumab (8 mg/kg for the first cycle, then 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21 day treatment cycle. MAIN OUTCOME MEASURE: The primary endpoint was investigator assessed progression-free survival. RESULTS: 590 patients were randomised and received treatment (297 in the pyrotinib group and 293 in the placebo group). As of 30 April 2024, during a median follow-up of 35.7 months in the pyrotinib group and 34.3 months in the placebo group, 59 (20%) and 87 (30%) patients died, respectively. Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004). At end of follow-up, neither group had reached the median overall survival. Improvement in progression-free survival in the pyrotinib group was maintained (22.1 months (95% CI 19.3 to 27.8) v 10.5 months (9.5 to 12.4), hazard ratio 0.44 (95% CI 0.36 to 0.53); nominal one sided P<0.001). Adverse event profiles remained consistent with the interim analysis for type, frequency, and severity. After discontinuation of docetaxel, the overall incidence of adverse events decreased substantially. As of 30 May 2025, with a median follow-up of 45.5 months, the pyrotinib based regimen showed consistent and prolonged survival benefit. CONCLUSIONS: The updated analysis of the phase 3 PHILA trial confirmed the superiority of pyrotinib in combination with trastuzumab and docetaxel over placebo in combination with trastuzumab and docetaxel in sustaining longer progression-free survival and improving overall survival for initial treatment of HER2 positive metastatic breast cancer. The safety profile remained consistent with interim findings, with no new safety signals identified during extended follow-up. This analysis reinforces the efficacy of this dual anti-HER2 (pyrotinib plus trastuzumab) regimen as an effective treatment strategy for this patient population. TRIAL REGISTRATION: ClinicalTrials.gov NCT03863223.

KM 提取结果

4 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig 2

Fig 2 Kaplan-Meier curve of PFS according to investigator in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer assigned to pyrotinib or placebo combined with trastuzumab and docetaxel in the full analysis set to 30 April 2024. CI=confidence interval; PFS=progression-free survival

Investigator_assessed_PFS_

PFS

Fig 2 · Panel Investigator_assessed_PFS_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Investigator_assessed_PFS_ 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig 4

Fig 4 Kaplan-Meier curve of progression-free survival in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer assigned to pyrotinib or placebo combined with trastuzumab and docetaxel in the full analysis set to 30 May 2025. CI=confidence interval

Fig_4_Kaplan-Meier_curve_of_progression-free_survival

Progression-free survival

Fig 4 · Panel Fig_4_Kaplan-Meier_curve_of_progression-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Fig_4_Kaplan-Meier_curve_of_progression-free_survival 是同一 Fig 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig 5

Fig 5 Kaplan-Meier curve of overall survival in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer assigned to pyrotinib or placebo combined with trastuzumab and docetaxel in the full analysis set to 30 April 2024. CI=confidence interval

Kaplan-Meier_curve_of_overall_survival

overall survival

Fig 5 · Panel Kaplan-Meier_curve_of_overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Kaplan-Meier_curve_of_overall_survival 是同一 Fig 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig 7

Fig 7 Kaplan-Meier curve of overall survival in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer assigned to pyrotinib or placebo combined with trastuzumab and docetaxel in the full analysis set to 30 May 2025. All reported P values are nominal one sided. CI=confidence interval; OS=overall survival

Overall_survival

OS

Fig 7 · Panel Overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_survival 是同一 Fig 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1 Trial profile of patients with human epidermal growth factor receptor 2 positive metastatic breast cancer assigned to pyrotinib or placebo combined with trastuzumab and docetaxel
非 KM Figure
Fig 3Fig 3 Forest plot of subgroup analysis of PFS in patients with HER2 positive metastatic breast cancer assigned to pyrotinib or placebo combined with trastuzumab and docetaxel. Hazard ratios are from unstratified analyses. The between subgroup effect estimate and 95% CI were post hoc analysis. *0 represents fully active and 1 represents ability to carry out light or sedentary work. †Determined by immunohistochemistry. CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; PFS=progression-free survival; PR=progesterone receptor
非 KM Figure
Fig 6Fig 6 Forest plot of subgroup analysis of overall survival in patients with HER2 positive metastatic breast cancer assigned to pyrotinib or placebo combined with trastuzumab and docetaxel. Hazard ratios are from unstratified analyses. The between subgroup effect estimate and 95% confidence interval were post hoc analysis. *0 represents fully active and 1 represents ability to carry out light or sedentary work. †Determined by immunohistochemistry. CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; PR=progesterone receptor
非 KM Figure